CMS(00867) announces its performance for 2025, with profit attributable to owners of approximately 1.489 billion yuan, a decrease of 8.08% year-on-year.

CMS (00867) announced its performance for 2025, with revenue increasing by 9.95% to HK$8.212 billion year-on-year. The company's attributable profit is approximately HK$1.489 billion, a decrease of 8.08% year-on-year. Basic earnings per share are HK$0.6154, with a proposed final dividend of HK$0.1366 per share. The group has adopted a "co-development + independent research and development" model to create an innovative engine with both near-end certainty and far-end growth. The "co-development" ensures richness and competitiveness in the short to medium-term pipeline and rapidly expands the product matrix; "independent research and development" strategically positions the group in cutting-edge technology fields, laying the foundation for long-term development and innovation. Since 2025, the group's innovation matrix continues to expand and improve: two new drugs have been approved for market, namely Balutu (Phosphorus Lutecitini Cream) for Vitiligo (approved for market in China in January 2026) and Dexidostaz Tazta Tablets (approved for market in China in March 2026). Existing innovative drugs are being rapidly scaled up, gradually forming a scale effect in promotion. Six innovative drugs are currently in the process of applying for new drug market authorization in China, providing momentum for future growth, including injection of Lobermilix (Y-3 injection) and newly added innovative products Slevemab Monoclonal Antibody Injection and Vikondo Monoclonal Antibody Injection, Phenylalanine Glucuronide Methylcellulose Enteric Tablets (ZUNVEYL), Comerichibai Monoclonal Antibody Injection (MG-K10 - Atopic Dermatitis (AD)), and Phosphorus Lutecitini Cream - AD (China NDA accepted in February 2026). The group delves deeply into the treatment of specialized diseases, beyond core markets, proactively expanding outpatient growth engines based on "new retail, digital channels, and consumer healthcare", catering to prescription outflow, diverse payment methods, and consumer health demands, strengthening channel and brand drive, and opening up incremental space with outpatient ecology. The group's skin health business, "Demag Medical", has already established a leading position in the Chinese skin health industry and plans to spin off and independently list on the main board of the Hong Kong Stock Exchange through introduction to the market and physical distribution, unlocking its independent value and high growth potential. Furthermore, the group actively deepens its "industrial internationalization" layout, building an efficient and coordinated system of the "research, production, and sales" full ecological chain. On July 15, 2025, the group successfully completed its second listing on the new exchange through introduction and used this as a pivot to promote deepening expansion in emerging markets, forming a multi-regional and sustainable growth new pattern. Looking back at 2025, CMS has achieved milestone strategic breakthroughs. In the future, with the comprehensive advancement of the "New Conzern" strategy, the group will continue to innovate as the source of power, continuously drive the diversified commercial ecology construction of internal and external collaboration, accelerate the realization of the advantages of the "industrial internationalization" system in emerging markets, and empower AI digital intelligence to run through operations and management. The group is steadily growing into an innovative-driven international pharmaceutical enterprise rooted in China, competing in global emerging markets, creating long-term value for the global pharmaceutical and healthcare industry.